RxMP Therapeutics
RxMP Therapeutics is dedicated to developing innovative therapies to prevent and treat hemorrhage and excessive bleeding. Their platform technology utilizes red cell-derived microparticles (RMPs) to stop bleeding with minimal risk of undesirable clotting. The company aims to bring transformative, marketable products that benefit both civilian and military health sectors, with a lead product candidate, RMP-402, showing significant market potential.
Industries
Nr. of Employees
small (1-50)
RxMP Therapeutics
16236 San Dieguito Road, Suite 2-10, P.O. Box 8071, Rancho Santa Fe, California 92067
Patents
Composition comprising red cell-derived microparticles and method of treating excessive bleeding
US-11241457-B2
View Details
Composition comprising red cell-derived microparticles and method of treating excessive bleeding
US-11241457-B2
View DetailsProducts
Allogeneic red cell–derived microparticle hemostatic agent (lead candidate)
A lyophilized, systemically administered hemostatic therapeutic produced from human packed red blood cells via high-pressure extrusion, designed to enhance platelet function and coagulation without causing off-target clotting; demonstrated efficacy in multiple preclinical bleeding models.
Allogeneic red cell–derived microparticle hemostatic agent (lead candidate)
A lyophilized, systemically administered hemostatic therapeutic produced from human packed red blood cells via high-pressure extrusion, designed to enhance platelet function and coagulation without causing off-target clotting; demonstrated efficacy in multiple preclinical bleeding models.
Services
Provision of lyophilized red cell–derived microparticles and related research materials to partner laboratories under cooperative research agreements for validation in large-animal hemorrhage models.
Provision of lyophilized red cell–derived microparticles and related research materials to partner laboratories under cooperative research agreements for validation in large-animal hemorrhage models.
Expertise Areas
- Hemostatic therapeutic development
- Cell-derived microparticle biomanufacturing
- Preclinical hemorrhage and trauma models
- Analytical assay development for microparticles
Key Technologies
- Cell-derived microparticles (microvesicles) production
- High-pressure extrusion for microparticle generation
- Lyophilization (freeze-drying) of biologic formulations
- Microparticle counting and particle size analysis
News & Updates
Enters Into Research & Development Agreement with Department of Defense’s Institute of Surgical Research
RxMP entered into a CRADA with the ISR to validate the effects of RMP-402 in promoting coagulation in large animal models of polytrauma hemorrhage and shock.
Reaches Consensus with FDA on GMP Allogeneic Manufacturing Process of RMP-402
RxMP received FDA approval to proceed with its proposed GMP manufacturing process of allogeneic RMP-402.
Appoints Shawna Khouri as Chief Operating Officer
Shawna Khouri was appointed as COO to lead operational strategy, bringing her extensive experience in biomedical engineering and innovation.
An update on the company's progress and outlook for 2024, featuring insights from CEO Dr. Rif Pamukcu and Dr. Mike Davis.
Company leaders provide updates on business initiatives and recent developments.
Concurrence with FDA on GMP manufacturing process
RxMP received FDA approval to proceed with GMP manufacturing of RMP-402, enabling large-scale production.
Enters Into Research & Development Agreement with Department of Defense’s Institute of Surgical Research
RxMP entered into a CRADA with the ISR to validate the effects of RMP-402 in promoting coagulation in large animal models of polytrauma hemorrhage and shock.
Reaches Consensus with FDA on GMP Allogeneic Manufacturing Process of RMP-402
RxMP received FDA approval to proceed with its proposed GMP manufacturing process of allogeneic RMP-402.
Appoints Shawna Khouri as Chief Operating Officer
Shawna Khouri was appointed as COO to lead operational strategy, bringing her extensive experience in biomedical engineering and innovation.
An update on the company's progress and outlook for 2024, featuring insights from CEO Dr. Rif Pamukcu and Dr. Mike Davis.
Company leaders provide updates on business initiatives and recent developments.
Concurrence with FDA on GMP manufacturing process
RxMP received FDA approval to proceed with GMP manufacturing of RMP-402, enabling large-scale production.